Abstract
To evaluate the dose- response effects of tiagabine on sleep and safety measures in healthy older adults. Randomized, double-blind, Latin-square design. Sleep laboratory. Twenty-four healthy older adults (11 men, 13 women; mean age 68.0 +/- 6.2 years) Tiagabine 2, 4, or 8 mg, or placebo, each given on two consecutive nights. Polysomnography revealed that compared with placebo, tiagabine 4 mg increased total sleep time, reduced wake after sleep onset, and increased minutes of slow-wave sleep. Tiagabine 8 mg decreased wake after sleep onset, increased slow-wave sleep, and improved a sleep-continuity index. No differences were seen between the 2-mg dose and placebo. Subjective ratings indicated fewer awakenings with the 8-mg dose. Central nervous system adverse events were somewhat higher in the 8-mg condition only. Measures of morning performance were minimally affected. Research with tiagabine at dosages of 8 mg or less appears warranted in elderly clinical populations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
